Skip to content

Composition for Treating Uterine Fibroid (SB-UF)

Uterine Fibroids Are a Prevalent Finding in Women of Reproductive Age. Ready Safety Study Extracts of Plants Pregnenolone, Pyridoxal Phosphate, and Dydrogesterone for Treating Uterine Fibroids in Women's Pregnancy.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04762316
Acronym
SB-UF
Enrollment
66
Registered
2021-02-21
Start date
2019-01-01
Completion date
2025-12-31
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Fibroids Affecting Pregnancy

Brief summary

Pregnenolone & Pyridoxal Phosphate SB-UF for treating uterine fibroids in women's pregnancies to lose the size of fibroids and to dissolve fibroids. Uterine fibroids are a very common finding in women pregnancy of reproductive age, fibroids fast grow in the first trimester of pregnancy. SB-UF against the rapid growth of fibroids under the influence of hormones during pregnancy. Use SB-UF to think about regulating stable Oestrogen levels and dissolving fibroids. This is a substantial insight into disease pathogenesis, with a clear path toward clinical application, which would lead to a substantial advance and perfection in management or public health policy.

Detailed description

Uterine fibroids are a very common finding in women's pregnancy of reproductive age fibroids fast grow in the first trimester of pregnancy. Clinically has shown that: * Uterine fibroids are associated with heavy or prolonged menstrual periods, and abnormal bleeding between menstrual periods. * Fibroids are associated with increased rates of spontaneous miscarriage, premature birth, placenta ablation, malpresentation, labor dysfunction, cesarean section, and postpartum hemorrhage, pain is the most common complication of fibroids uterus during pregnancy. * Use the composition that has sufficient Pregnenolone, and coenzyme Pyridoxal Phosphate, and combined with Dydrogesterone, this preparation will soften uterine fibroids and disappear fibroids. Pregnenolone is produced in the adrenal glands and the central nervous system. Pregnenolone is synthesized from Cholesterol and it is the precursor of Progesterone, Estrogen, and dehydroepiandrosterone (DHEA). In some people Pregnenolone will decrease with age, which will lead to an imbalance between Progesterone and estrogen, according to research, this imbalance is the cause of abnormal growth of the uterine muscle fibers cells that produce multiple fibroids in the womb. Supplementation Pregnenolone is necessary for women of childbearing and reproductive age, overtime tracking pregnant women but there were fibroids from before pregnancy these fibroids will develop very quickly to stun the fetus many problems in pregnancy, and childbirth, the risk of miscarriage, preterm delivery,...The new drug will maintain a sufficient amount of Pregnenolone natural is the essence from Dioscorea persimilis prain & burkill and associated with a necessary element is Coenzyme Pyridoxal Phosphate, Dydrogesterone. Compound presence in the body will curb the development of the muscle fibers uterus, the muscle fibers in the fibroids will soften, spread out, and disappear fibroids. The uterus returns to its normal state, the fetus will develop naturally. Research results * After 40 weeks of ultrasound examination: * 100% of women using SB-UF drugs have the disappearance of fibroids, only the image of uterine muscle is thicker than usual. * 100% of women who received SB-UF placebo did not experience any beneficial progress. * Through study completion, an average of 40 weeks

Interventions

DRUGSB-UF

Dosage: -Take 1tablet/2 times/day/in throughout pregnancy.

DEVICESB-UF Placebo

Dosage: -Take 1tablet/2 times/day/in throughout pregnancy.

Sponsors

Trieu, Nguyen Thi, M.D.
Lead SponsorINDIV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

The number of post-recruiting people who have fibroids is divided into 2 groups * The group of pregnancy uterine fibroids uses drugs under study. * The group of pregnancy uterine fibroids uses a placebo

Intervention model description

Selection of women ages 18 to 40, with pregnancy uterine fibroids and pregnancy in the 8th week of pregnancy.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Procedure to the treatment of fibroids in pregnancy and in women desiring future fertility.

Exclusion criteria

* Subserosal fibroids may be pedunculated hanging from a stalk inside or outside the uterus.

Design outcomes

Primary

MeasureTime frameDescription
Use SB-UF drugs to lose the size of Uterine Fibroids on Women the Pregnancy.40 weeksMeasuring the size of uterine fibroid. Monitor the disappearance of benign smooth muscle cell tumors of the uterus

Countries

Vietnam

Contacts

PRINCIPAL_INVESTIGATORThi Trieu Nguyen, Dr.

Trieu, Nguyen Thi, M.D.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 9, 2026